Skip to main content

Supernus Pharm(SUPN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low46.83
Day High49.29
Open:49.09
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

Top Stories: Supernus Pharm

Select a category then submit the form to load news
StockStory
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
SUPN
Tipranks
Supernus Pharmaceuticals Braces for 2025 U.S. Drug Pricing Orders and MFN Rules That Threaten Revenues and Global Expansion
Tipranks
Supernus Pharmaceuticals Balances Record Sales With Rising Costs
Tipranks
Analysts Conflicted on These Healthcare Names: Valneva (VALN) and Supernus Pharmaceuticals (SUPN)
Tipranks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oxford BioMedica (OtherOXBDF), Valneva (VALN) and Supernus Pharmaceuticals (SUPN)
Tipranks
Supernus Pharmaceuticals (SUPN) Receives a Hold from Stifel Nicolaus
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Supernus boosts executive pay with new equity incentives
StockStory
Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales
SUPN
GlobeNewswire
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire
Supernus Pharmaceuticals to Participate in March Investor Conferences
StockStory
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
SUPN
Tipranks
Jefferies Reaffirms Their Buy Rating on Supernus Pharmaceuticals (SUPN)
GlobeNewswire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
StockStory
3 Reasons to Avoid SUPN and 1 Stock to Buy Instead
SUPN
GlobeNewswire
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
StockStory
1 Cash-Heavy Stock on Our Buy List and 2 We Brush Off
NSSC
Tipranks
Supernus Revises Merger Milestone Payment Obligations Agreement
Tipranks
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)
StockStory
1 Healthcare Stock to Consider Right Now and 2 We Brush Off
VRTX
StockStory
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
NTRA
StockStory
3 Unprofitable Stocks We Steer Clear Of
VRNS
Tipranks
Bank of America Securities Remains a Buy on Supernus Pharmaceuticals (SUPN)
Tipranks
Supernus Pharmaceuticals (SUPN) Receives a Buy from Piper Sandler
Tipranks
Cantor Fitzgerald Remains a Buy on Supernus Pharmaceuticals (SUPN)
Tipranks
Bank of America Securities Keeps Their Buy Rating on Supernus Pharmaceuticals (SUPN)
StockStory
3 Low-Volatility Stocks We’re Skeptical Of
LKQ
StockStory
3 of Wall Street’s Favorite Stocks That Concern Us
PTLO
Motley Fool
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back
StockStory
1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down
PRVA
StockStory
3 Stocks Under $50 That Concern Us
PRDO
StockStory
3 Unprofitable Stocks We Find Risky
AAP

Profile

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.